tiprankstipranks
Siemens Healthineers AG Unsponsored ADR (SMMNY)
OTHER OTC:SMMNY
US Market
Want to see SMMNY full AI Analyst Report?

Siemens Healthineers AG Unsponsored ADR (SMMNY) Price & Analysis

5 Followers

SMMNY Stock Chart & Stats

$19.95
$0.40(2.02%)
At close: 4:00 PM EDT
$19.95
$0.40(2.02%)

Bulls Say, Bears Say

Bulls Say
Recurring Revenue From Services & ConsumablesSiemens Healthineers' installed base drives recurring service, consumables and testing revenues, creating predictable cash flows and higher lifetime customer value. This recurring mix cushions equipment cyclicality, supports steady FCF, and funds R&D and long-term strategic investments.
Product And Technology LeadershipStrong adoption of advanced imaging platforms (photon-counting CT, DryCool MR) and a refreshed interventional portfolio indicate durable competitive differentiation. Technology leadership accelerates replacement cycles, supports premium pricing and service attach rates, and helps capture share in capital equipment markets.
Robust Cash Generation And DeleveragingConsistent FCF generation and a meaningful reduction in net debt improve financial flexibility and fund strategic priorities. Strong cash conversion enables ongoing R&D, capital investments, dividend and separation-related costs while reducing refinancing risk and supporting gradual leverage normalization.
Bears Say
Diagnostics Revenue Weakness (China)A sustained rebase in the Chinese diagnostics market and legacy-platform dilution create prolonged top-line and margin pressure in Diagnostics. Given Diagnostics' recurring-consumables role, persistent weakness reduces revenue visibility and undermines aggregate margin sustainability over the medium term.
High Absolute Debt And Leverage ExposureAlthough leverage has improved, sizable absolute debt limits strategic flexibility and heightens sensitivity to higher rates or slower cash flow. Expected deterioration in financial income and higher refinancing costs will pressure net income and could constrain capital allocation in adverse scenarios.
One-time Tariff Refunds Masking FundamentalsTariff refunds provided a temporary EPS and margin uplift, obscuring underlying performance—particularly within Diagnostics. Reliance on one-off benefits can mislead stakeholders on sustainable profitability and hides incremental inflation, separation and refinancing headwinds that will affect future earnings.

Siemens Healthineers AG Unsponsored ADR News

SMMNY FAQ

What was Siemens Healthineers AG Unsponsored ADR’s price range in the past 12 months?
Siemens Healthineers AG Unsponsored ADR lowest stock price was $19.35 and its highest was $28.79 in the past 12 months.
    What is Siemens Healthineers AG Unsponsored ADR’s market cap?
    Siemens Healthineers AG Unsponsored ADR’s market cap is $47.43B.
      When is Siemens Healthineers AG Unsponsored ADR’s upcoming earnings report date?
      Siemens Healthineers AG Unsponsored ADR’s upcoming earnings report date is Nov 05, 2026 which is in 92 days.
        How were Siemens Healthineers AG Unsponsored ADR’s earnings last quarter?
        Siemens Healthineers AG Unsponsored ADR released its earnings results on Jul 31, 2026. The company reported $0.403 earnings per share for the quarter, beating the consensus estimate of $0.302 by $0.101.
          Is Siemens Healthineers AG Unsponsored ADR overvalued?
          According to Wall Street analysts Siemens Healthineers AG Unsponsored ADR’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Siemens Healthineers AG Unsponsored ADR pay dividends?
            Siemens Healthineers AG Unsponsored ADR pays a Annually dividend of $0.594 which represents an annual dividend yield of 2.81%. See more information on Siemens Healthineers AG Unsponsored ADR dividends here
              What is Siemens Healthineers AG Unsponsored ADR’s EPS estimate?
              Siemens Healthineers AG Unsponsored ADR’s EPS estimate is 0.39.
                How many shares outstanding does Siemens Healthineers AG Unsponsored ADR have?
                Siemens Healthineers AG Unsponsored ADR has 2,256,000,000 shares outstanding.
                  What happened to Siemens Healthineers AG Unsponsored ADR’s price movement after its last earnings report?
                  Siemens Healthineers AG Unsponsored ADR reported an EPS of $0.403 in its last earnings report, beating expectations of $0.302. Following the earnings report the stock price went down -0.897%.
                    Which hedge fund is a major shareholder of Siemens Healthineers AG Unsponsored ADR?
                    Currently, no hedge funds are holding shares in SMMNY
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Siemens Healthineers AG Unsponsored ADR Stock Smart Score

                      Company Description

                      Siemens Healthineers AG Unsponsored ADR

                      Siemens Healthineers AG (SMMNY), operating through its various subsidiaries, is a global enterprise that provides a comprehensive suite of diagnostic and therapeutic medical products and services. These offerings are extended to healthcare professionals and institutions across numerous international markets, including Germany, the United States, the broader European continent, the CIS region, Africa, the Middle East, the Americas, the Asia Pacific region, Japan, and China. The company's business is structured across four primary divisions: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment supplies cutting-edge systems such as magnetic resonance imaging (MRI), computed tomography (CT), X-ray, molecular imaging, and ultrasound technologies. It also develops sophisticated software solutions designed to streamline the interpretation and structured reporting of diagnostic images from diverse modalities. The Diagnostics segment delivers in-vitro diagnostic products and associated services, catering to healthcare providers in both general and specialized laboratory settings, as well as point-of-care diagnostics. This division further offers workflow solutions to optimize laboratory operations and provides advanced informatics products. The Varian segment specializes in oncology solutions, featuring advanced technologies like microwave, cryoablation, and embolization. It also furnishes extensive clinical professional services and tailored support programs to assist oncology departments in hospitals and clinics with their cancer care operations. The Advanced Therapies segment focuses on developing products that facilitate image-guided, minimally invasive clinical procedures. These solutions are applied across various medical specialties, including cardiology, neurology, and oncology. Its portfolio includes angiography systems, mobile C-arms, and AI-powered clinical applications that enhance procedural precision. Beyond its core product lines, Siemens Healthineers AG offers a broad range of essential technical customer services. These include maintenance and repair, provision of spare parts, medical equipment performance management, training programs, clinical education, e-learning resources, planning and design assistance, financing options, asset management, and managed departmental services for laboratories and other healthcare facilities. The company also provides healthcare consulting, products, and additional services. Established in 1896, Siemens Healthineers AG maintains its corporate headquarters in Forchheim, Germany, and functions as a subsidiary of Siemens Aktiengesellschaft.

                      Siemens Healthineers AG Unsponsored ADR (SMMNY) Earnings & Revenues

                      SMMNY Company Deck

                      SMMNY Earnings Call

                      Q3 2026
                      0:00 / 0:00
                      Earnings Call Sentiment|Neutral
                      The call presented a mix of strong operational and commercial momentum (solid book-to-bill, strategic value partnerships, product adoption in photon-counting CT and DryCool MR, radiopharma growth, cash generation and deleveraging) while highlighting material headwinds from a persistent Diagnostics revenue decline (notably in China), a downward revision to revenue guidance, and inflationary and refinancing pressures. Tariff refunds provided a one-time boost to margins and EPS, but underlying challenges in Diagnostics and supply-chain inflation remain important near-term risks. Management expects a Q4 acceleration in the synergetic core but keeps a cautious stance on Diagnostics and FY2027 uncertainties.View all SMMNY earnings summaries
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Abbott Laboratories
                      Boston Scientific
                      Koninklijke Philips
                      Medtronic
                      Stryker
                      Popular Stocks